{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:29:59Z","timestamp":1794072599693,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007345","name":"Cancer Center","doi-asserted-by":"crossref","award":["P30 CA008748-50"],"award-info":[{"award-number":["P30 CA008748-50"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.eururo.2019.06.015","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T01:15:53Z","timestamp":1563412553000},"page":"754-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights"],"prefix":"10.1016","volume":"76","author":[{"given":"Maria I.","family":"Carlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ari","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn R.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.06.015_bib0430","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2019.06.015_bib0435","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.eururo.2017.06.040","article-title":"Recommendations for the management of rare kidney cancers","volume":"72","author":"Giles","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0440","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0445","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2010.08.031","article-title":"Hereditary renal cancer syndromes: an update of a systematic review","volume":"58","author":"Verine","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2019.06.015_bib0455","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.eururo.2019.06.015_bib0460","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0465","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1002\/cncr.30893","article-title":"Advances in the diagnosis of hereditary kidney cancer: initial results of a multigene panel test","volume":"123","author":"Nguyen","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0470","doi-asserted-by":"crossref","first-page":"238.e1","DOI":"10.1016\/j.urolonc.2015.11.021","article-title":"Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes","volume":"34","author":"Stratton","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0475","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0480","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ucl.2016.12.002","article-title":"Hereditary kidney cancer syndromes and surgical management of the small renal mass","volume":"44","author":"Nguyen","year":"2017","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2019.06.015_bib0485","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2018.79.2523","article-title":"Genetic predisposition to renal cell carcinoma: implications for counseling, testing, screening, and management","volume":"36","author":"Shuch","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0490","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)68930-6","article-title":"Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery","volume":"161","author":"Walther","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0495","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-5347(05)66524-X","article-title":"Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience","volume":"165","author":"Herring","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0500","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2015.65.6140","article-title":"Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome","volume":"34","author":"Nielsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2019.06.015_bib0510","doi-asserted-by":"crossref","first-page":"11588","DOI":"10.1038\/ncomms11588","article-title":"Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours","volume":"7","author":"Fei","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2019.06.015_bib0515","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","article-title":"Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype","volume":"5","author":"Chen","year":"1995","journal-title":"Hum Mutat"},{"key":"10.1016\/j.eururo.2019.06.015_bib0520","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.eururo.2019.06.015_bib0525","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0530","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5858\/arpa.2011-0485-RA","article-title":"Spectrum of preneoplastic and neoplastic cystic lesions of the kidney","volume":"136","author":"Chen","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.eururo.2019.06.015_bib0535","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ki.1996.395","article-title":"Renal involvement in von Hippel-Lindau disease","volume":"50","author":"Chauveau","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.eururo.2019.06.015_bib0540","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.humpath.2014.06.004","article-title":"Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome\u2014clinicopathological features and comparative genomic analysis of 3 cases","volume":"45","author":"Rao","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0545","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/PAS.0b013e318282dab8","article-title":"Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma","volume":"37","author":"Williamson","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0550","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","article-title":"The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease","volume":"172","author":"Duffey","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0555","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.juro.2012.08.038","article-title":"Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup","volume":"188","author":"Singer","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0560","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0565","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0570","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4143\/crt.2013.45.4.349","article-title":"Sunitinib treatment for metastatic renal cell carcinoma in patients with von Hippel-Lindau disease","volume":"45","author":"Kim","year":"2013","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.eururo.2019.06.015_bib0575","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1172\/JCI73665","article-title":"Pharmacological HIF2alpha inhibition improves VHL disease-associated phenotypes in zebrafish model","volume":"125","author":"Metelo","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2019.06.015_bib0580","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/MCB.00483-09","article-title":"Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species","volume":"29","author":"Sudarshan","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2019.06.015_bib0590","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","article-title":"Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling","volume":"20","author":"Adam","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2019.06.015_bib0595","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ccr.2011.08.024","article-title":"An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma","volume":"20","author":"Ooi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2019.06.015_bib0600","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","article-title":"Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors","volume":"26","author":"Xiao","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.eururo.2019.06.015_bib0605","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","article-title":"Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition","volume":"537","author":"Sciacovelli","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2019.06.015_bib0610","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0615","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0620","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0625","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0630","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase-deficient kidney cancer\u2014targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.06.015_bib0635","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2019.06.015_bib0640","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000719","article-title":"Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma","volume":"40","author":"Smith","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0645","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0650","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0655","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0660","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0665","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/his.13395","article-title":"Re-evaluation of 33 \u2018unclassified\u2019 eosinophilic renal cell carcinomas in young patients","volume":"72","author":"Li","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2019.06.015_bib0670","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/his.13183","article-title":"A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma","volume":"71","author":"Smith","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2019.06.015_bib0675","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrurol.2010.234","article-title":"Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC","volume":"8","author":"Yamasaki","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0680","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrurol.2015.206","article-title":"Molecular genetics and clinical features of Birt-Hogg-Dube syndrome","volume":"12","author":"Schmidt","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0685","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jnci\/dji154","article-title":"High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors","volume":"97","author":"Vocke","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.06.015_bib0690","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/430842","article-title":"Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome","volume":"76","author":"Schmidt","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0695","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/bjc.2011.463","article-title":"Renal cancer and pneumothorax risk in Birt-Hogg-Dube syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families","volume":"105","author":"Houweling","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0700","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","article-title":"Renal tumors in the Birt-Hogg-Dube syndrome","volume":"26","author":"Pavlovich","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0705","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/00000478-199909000-00013","article-title":"Renal oncocytosis: a morphologic study of fourteen cases","volume":"23","author":"Tickoo","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0710","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","article-title":"Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype","volume":"155","author":"Lubensky","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0715","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II: and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0720","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0725","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2012.08.030","article-title":"Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer","volume":"188","author":"Ricketts","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0730","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/modpathol.2014.86","article-title":"Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma","volume":"28","author":"Williamson","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0735","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0740","first-page":"1","article-title":"Persistent severe hyperlactatemia and metabolic derangement in lethal SDHB-mutated metastatic kidney cancer: clinical challenges and examples of extreme Warburg effect","volume":"1","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0745","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e318227e7f4","article-title":"Renal tumors associated with germline SDHB mutation show distinctive morphology","volume":"35","author":"Gill","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0750","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0755","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2019.06.015_bib0760","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2019.06.015_bib0765","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0770","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2019.06.015_bib0775","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0780","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.06.015_bib0785","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(18)30648-X","article-title":"Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study","volume":"19","author":"Voss","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0790","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0795","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.06.015_bib0800","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.path.2018.07.010","article-title":"Recognizing hereditary renal cancers through the microscope: a pathology update","volume":"11","author":"Peng","year":"2018","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.eururo.2019.06.015_bib0805","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","article-title":"Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients","volume":"38","author":"Guo","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0810","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","article-title":"Renal cell carcinoma in tuberous sclerosis complex","volume":"38","author":"Yang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0815","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PAS.0000000000001170","article-title":"Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm","volume":"43","author":"Chen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0820","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2018.06.007","article-title":"Somatic bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0825","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2019.06.015_bib0830","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.06.015_bib0835","doi-asserted-by":"crossref","first-page":"1187.e1","DOI":"10.1016\/j.urology.2011.12.025","article-title":"Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome","volume":"79","author":"Mester","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.06.015_bib0840","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.juro.2013.06.012","article-title":"Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer","volume":"190","author":"Shuch","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0845","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1210\/jc.2017-01249","article-title":"CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism","volume":"102","author":"van der Tuin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2019.06.015_bib0850","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/gcc.20718","article-title":"Population-based survey of cancer risks in chromosome 3 translocation carriers","volume":"49","author":"Woodward","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0855","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10689-013-9657-4","article-title":"Diagnosis and management of BHD-associated kidney cancer","volume":"12","author":"Stamatakis","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0860","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"International Tuberous Sclerosis Complex Consensus G: Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.eururo.2019.06.015_bib0865","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1158\/1078-0432.CCR-17-0629","article-title":"PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood","volume":"23","author":"Schultz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.06.015_bib0870","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","article-title":"Von Hippel-Lindau and Hereditary Pheochromocytoma\/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood","volume":"23","author":"Rednam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.06.015_bib0875","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.12.022","article-title":"Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy","volume":"92","author":"Star","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2019.06.015_bib0880","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2019.06.015_bib0885","series-title":"CDC73-Related Disorders","author":"Hyde","year":"1993"},{"key":"10.1016\/j.eururo.2019.06.015_bib0890","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.14.13514","article-title":"Diagnostic approach to hereditary renal cell carcinoma","volume":"204","author":"Gupta","year":"2015","journal-title":"AJR Am J Roentgenol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819305007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819305007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:05:49Z","timestamp":1759583149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819305007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0302283819305007"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.06.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}